The quarter's performance reflects the inherent seasonality in Dabur's business, with the March quarter traditionally being the weakest period due to lower demand for health supplements and beverages. Revenue declined 14.63% sequentially to ₹3,038.02 crores, whilst operating margins compressed significantly to 15.20% from 20.63% in the previous quarter. Despite the sequential weakness, the company managed to post healthy year-on-year growth across key metrics, suggesting underlying business resilience.
The results come at a time when the stock has been under pressure, declining 10.25% over five years whilst the Sensex surged 57.50%, resulting in a negative alpha of 67.75 percentage points. However, recent momentum has been encouraging, with the stock gaining 12.30% over the past month and 8.70% over the past week, significantly outperforming the broader market.
Financial Performance: Seasonal Headwinds Impact Margins
Dabur India's Q4 FY26 financial performance was characterised by pronounced sequential weakness, typical of the company's seasonal business pattern. Net sales declined 14.63% quarter-on-quarter to ₹3,038.02 crores, whilst consolidated net profit fell 34.18% to ₹368.60 crores. The year-on-year comparison, however, painted a more favourable picture, with revenue growing 7.35% and net profit advancing 15.14%, indicating that the company has managed to improve its operational efficiency compared to the previous year's corresponding quarter.
| Quarter | Net Sales (₹ Cr) | QoQ Change | Net Profit (₹ Cr) | QoQ Change | Operating Margin |
|---|---|---|---|---|---|
| Mar'26 | 3,038.02 | -14.63% | 368.60 | -34.18% | 15.20% |
| Dec'25 | 3,558.65 | +11.51% | 559.97 | +23.74% | 20.63% |
| Sep'25 | 3,191.32 | -6.26% | 452.55 | -11.94% | 18.43% |
| Jun'25 | 3,404.58 | +20.30% | 513.91 | +60.53% | 19.62% |
| Mar'25 | 2,830.14 | -15.65% | 320.13 | -38.72% | 15.08% |
| Dec'24 | 3,355.25 | +10.79% | 522.38 | +22.91% | 20.32% |
| Sep'24 | 3,028.59 | — | 425.00 | — | 18.24% |
The margin compression was particularly severe in Q4 FY26, with operating margins (excluding other income) declining 543 basis points sequentially to 15.20%, down from 20.63% in Q3 FY26. This marks the lowest quarterly margin in the trailing twelve-month period and reflects the seasonal nature of Dabur's product portfolio, which includes health supplements and beverages that see weaker demand during the March quarter. PAT margins also contracted to 11.92% from 15.56% in the previous quarter.
On a full-year basis for FY25, Dabur reported net sales of ₹12,563 crores, representing modest growth of 1.30% over FY24. Operating profit (excluding other income) stood at ₹2,316 crores with an operating margin of 18.40%, down 90 basis points from 19.30% in FY24. The company's profit after tax for FY25 came in at ₹1,739 crores, declining 3.98% from ₹1,811 crores in FY24, reflecting the challenging operating environment and margin pressures.
Operational Challenges: Growth Deceleration and Profitability Concerns
Dabur India's operational performance over recent quarters reveals a concerning trend of decelerating growth and persistent margin pressures. The company's five-year sales growth stands at a modest 7.39% annually, whilst operating profit (EBIT) has grown at an even more anaemic 3.06% per annum over the same period. This significant divergence between topline and bottomline growth rates highlights the structural margin compression the company has experienced.
The company's return on equity (ROE) averaged 18.97% over recent years, which, whilst respectable, represents a decline from historical levels. Higher ROE indicates better capital efficiency and profitability, and Dabur's ROE of approximately 19% places it in the middle tier among FMCG peers. The latest ROE stands at 16.51%, suggesting some deterioration in capital efficiency. The company's return on capital employed (ROCE) averaged 23.23%, with the latest figure at 24.16%, indicating reasonably efficient deployment of capital despite margin pressures.
One positive aspect of Dabur's operational profile is its strong balance sheet. The company maintains a net cash position, with average net debt to equity of -0.28, meaning it has more cash than debt. Debt to EBITDA stands at a comfortable 0.50, and interest coverage (EBIT to interest) is robust at 26.22 times on average. This financial flexibility provides the company with ample room to invest in growth initiatives or weather temporary demand slowdowns.
âš ï¸ Key Concern: Non-Operating Income Dependency
In Q4 FY26, other income (non-operating income) constituted 36.95% of profit before tax, standing at ₹175.03 crores against PBT of ₹473.68 crores. This high proportion of non-core income raises questions about the sustainability of reported profitability and suggests that core operating performance is weaker than headline numbers indicate. Investors should monitor whether the company can improve core operating profitability in coming quarters.
The company's working capital management appears efficient, with the debtors turnover ratio reaching its highest level at 18.44 times on a half-yearly basis. This indicates that Dabur is collecting receivables quickly, which is crucial for maintaining healthy cash flows in the FMCG business. However, interest costs in Q4 FY26 reached their highest quarterly level at ₹39.97 crores, reflecting increased borrowings or higher interest rates, which warrants monitoring.
Industry Context: FMCG Sector Headwinds Persist
The FMCG sector in India has been grappling with multiple challenges, including subdued rural demand, intense competition, and input cost volatility. Dabur's performance must be viewed within this broader industry context, where even established players have struggled to maintain historical growth rates and margins. The company's 7.35% year-on-year revenue growth in Q4 FY26, whilst positive, reflects the tepid demand environment that has characterised the sector.
Dabur's product portfolio, heavily weighted towards health and wellness categories including health supplements, oral care, and hair care, makes it particularly vulnerable to seasonal demand fluctuations. The March quarter typically sees lower consumption of health supplements and beverages, which explains the sequential revenue decline of 14.63%. This seasonality pattern is consistent with historical trends, and investors should evaluate the company's performance over full-year periods rather than focusing excessively on individual quarters.
The company's Ayurvedic positioning provides both opportunities and challenges. Whilst the growing consumer preference for natural and herbal products offers a structural tailwind, the category also faces intense competition from both established players and new-age brands. Dabur's ability to maintain market share whilst defending margins will be crucial for long-term value creation.
Peer Comparison: Valuation and Performance Metrics
When benchmarked against industry peers, Dabur India's valuation and operational metrics present a mixed picture. The company trades at a price-to-earnings ratio of 44.53 times trailing twelve-month earnings, which is below the FMCG sector average but still represents a significant premium to the broader market. This valuation must be justified by superior growth prospects or competitive advantages, which appear somewhat elusive given the company's recent performance trajectory.
| Company | P/E (TTM) | P/BV | ROE (%) | Debt/Equity | Div Yield (%) |
|---|---|---|---|---|---|
| Dabur India | 44.53 | 7.55 | 18.97 | -0.28 | 1.71 |
| ITC | 15.94 | 5.42 | 27.82 | -0.26 | 2.11 |
| Nestle India | 83.97 | 55.18 | 65.72 | -0.17 | 0.81 |
| Britannia Inds. | 57.95 | 37.49 | 74.67 | 0.34 | 1.29 |
| Tata Consumer | 79.15 | 5.65 | 6.78 | 0.01 | 0.71 |
| Godrej Consumer | 52.33 | 8.72 | 14.97 | 0.12 | 1.93 |
Dabur's ROE of 18.97% lags significantly behind premium FMCG players such as Nestle India (65.72%) and Britannia Industries (74.67%), though it compares favourably with Godrej Consumer Products (14.97%) and substantially outperforms Tata Consumer (6.78%). The company's price-to-book value of 7.55 times is considerably lower than Nestle (55.18x) and Britannia (37.49x), suggesting that the market is not according Dabur the same quality premium as these peers.
Dabur's dividend yield of 1.71% is competitive within the peer group, exceeding most competitors except ITC (2.11%) and Godrej Consumer (1.93%). The company's dividend payout ratio of 80.21% is notably high, indicating that management is returning a substantial portion of profits to shareholders. Whilst this is shareholder-friendly, it also suggests limited reinvestment for growth, which could constrain future expansion.
The company's net cash position (debt to equity of -0.28) is a clear competitive advantage, providing financial flexibility that some peers lack. However, this balance sheet strength has not translated into superior operating performance or market-beating returns, raising questions about capital allocation efficiency.
Valuation Analysis: Premium Difficult to Justify
Dabur India's current valuation appears stretched relative to its growth prospects and recent operational performance. Trading at 44.53 times trailing earnings, the stock commands a significant premium to the broader market, despite delivering underwhelming growth rates. The company's PEG ratio of 13.38 is particularly concerning, indicating that investors are paying dearly for each unit of earnings growth.
The stock's enterprise value to EBITDA multiple of 32.97 times and EV to EBIT of 40.80 times further underscore the expensive valuation. These multiples are elevated even by FMCG sector standards and appear difficult to justify given the company's 3.06% five-year EBIT growth rate. The EV to sales multiple of 6.14 times, whilst not extreme for the sector, still implies high expectations for margin expansion and growth acceleration.
The stock's current price of ₹479.90 sits 16.80% below its 52-week high of ₹576.80, but remains 19.66% above the 52-week low of ₹401.05. This positioning suggests that whilst the stock has corrected from peak levels, it has not reached deeply oversold territory that might represent a compelling entry point. The valuation grade has been classified as "Expensive" by proprietary metrics, having oscillated between "Expensive" and "Very Expensive" over recent months.
Given the company's modest growth trajectory, margin pressures, and high valuation multiples, it is challenging to construct a bullish case based on valuation alone. The stock would need to demonstrate significant operational improvements or growth acceleration to justify current price levels. A fair value estimate would likely be 15-20% below current levels, implying downside risk rather than upside potential.
Shareholding Pattern: Promoter Stability, FII Exodus
Dabur India's shareholding pattern reveals a stable promoter base but concerning trends in institutional ownership. Promoter holding stood at 66.25% as of March 2026, showing minimal sequential change of just 0.02 percentage points. This stability is reassuring, as it indicates long-term commitment from the founding family and reduces concerns about governance or strategic direction changes.
| Shareholder Category | Mar'26 | Dec'25 | Sep'25 | Jun'25 | Mar'25 |
|---|---|---|---|---|---|
| Promoter | 66.25% | 66.23% | 66.22% | 66.22% | 66.27% |
| FII | 9.98% â–¼ | 10.05% â–¼ | 10.89% â–¼ | 11.85% â–¼ | 12.68% |
| Mutual Funds | 7.10% â–¼ | 7.28% â–¼ | 8.04% â–² | 7.02% â–² | 6.23% |
| Insurance | 10.02% â–² | 9.67% â–² | 7.99% â–² | 7.71% â–² | 7.23% |
| Other DII | 1.45% | 1.43% | 1.37% â–¼ | 1.51% â–¼ | 2.22% |
| Non-Institutional | 5.21% | 5.34% | 5.50% | 5.70% â–² | 5.36% |
However, foreign institutional investor (FII) holdings have declined consistently over the past year, falling from 12.68% in March 2025 to 9.98% in March 2026, representing a reduction of 270 basis points. This sustained selling by sophisticated international investors suggests waning confidence in the company's near-term prospects. The sequential decline of 7 basis points in the most recent quarter continues this negative trend.
Mutual fund holdings have also declined sequentially, dropping from 7.28% in December 2025 to 7.10% in March 2026, though they remain higher than the 6.23% level seen in March 2025. The reduction of 18 basis points quarter-on-quarter indicates that domestic institutional investors are also trimming positions, albeit more modestly than their foreign counterparts.
On a positive note, insurance company holdings have increased substantially, rising from 7.23% in March 2025 to 10.02% in March 2026, with a sequential gain of 35 basis points in the most recent quarter. This increase of 279 basis points over four quarters suggests that long-term institutional investors continue to see value in Dabur's franchise, even as other categories reduce exposure. The absence of any promoter pledging is another positive signal, indicating that the controlling shareholders are not under financial stress.
Stock Performance: Short-Term Recovery Amidst Long-Term Underperformance
Dabur India's stock price performance presents a stark contrast between recent momentum and long-term underperformance. The shares have gained 12.30% over the past month and 8.70% over the past week, significantly outperforming the Sensex which declined 0.08% and gained 0.76% over the same respective periods. This recent strength has pushed the stock to ₹479.90, though it remains well below the 52-week high of ₹576.80.
| Period | Stock Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Week | +8.70% | +0.76% | +7.94% |
| 1 Month | +12.30% | -0.08% | +12.38% |
| 3 Months | -5.62% | -7.27% | +1.65% |
| 6 Months | -7.50% | -6.87% | -0.63% |
| YTD | -4.65% | -9.06% | +4.41% |
| 1 Year | +2.27% | -3.53% | +5.80% |
| 2 Years | -13.79% | +5.49% | -19.28% |
| 3 Years | -6.62% | +25.48% | -32.10% |
| 5 Years | -10.25% | +57.50% | -67.75% |
However, the longer-term picture is deeply concerning. Over two years, the stock has declined 13.79% whilst the Sensex gained 5.49%, resulting in negative alpha of 19.28 percentage points. Over three years, Dabur has fallen 6.62% against a Sensex gain of 25.48%, producing negative alpha of 32.10 percentage points. The five-year performance is even more disappointing, with the stock declining 10.25% whilst the Sensex surged 57.50%, creating a massive negative alpha of 67.75 percentage points.
This sustained underperformance reflects the market's growing concerns about Dabur's ability to generate profitable growth. The stock's beta of 1.20 indicates it is more volatile than the broader market, amplifying both gains and losses. With a volatility of 22.01% over the past year compared to the Sensex's 13.48%, Dabur has delivered higher risk without commensurate returns, resulting in a poor risk-adjusted performance.
The technical picture shows the stock trading below all major moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. The overall technical trend is classified as "Mildly Bearish," having changed from "Bearish" on May 5, 2026. Most technical indicators including MACD and KST remain bearish on both weekly and monthly timeframes, suggesting that the recent bounce may be a temporary relief rally rather than a sustained trend reversal.
Investment Thesis: Quality Company, Expensive Valuation, Uncertain Growth
Dabur India's investment thesis rests on three key pillars: quality, valuation, and growth prospects. The company scores well on quality metrics, classified as a "Good" quality company based on long-term financial performance. It maintains zero net debt, generates positive cash flows, exhibits no promoter pledging, and has a track record of consistent dividend payments. The average ROE of 18.97% and ROCE of 23.23% indicate reasonable capital efficiency, though these metrics have been trending lower.
However, valuation remains a significant headwind. The stock is classified as "Expensive" with a P/E ratio of 44.53 times and an alarming PEG ratio of 13.38, indicating that investors are paying a steep premium for anaemic growth. The EV/EBITDA multiple of 32.97 times and EV/EBIT of 40.80 times further underscore the rich valuation, which appears difficult to justify given the company's 7.39% five-year sales growth and 3.06% EBIT growth.
The financial trend is classified as "Negative," with quarterly profit before tax (less other income) falling 33.90% versus the previous four-quarter average, and net sales declining 6.40% against the same benchmark. Interest costs have reached their highest quarterly level, and non-operating income constitutes an elevated 36.95% of profit before tax, raising sustainability concerns about reported profitability.
The technical trend is "Mildly Bearish," with the stock trading below all major moving averages and most momentum indicators flashing bearish signals. Whilst recent price action has been positive, the longer-term technical picture remains unconvincing. The combination of expensive valuation, negative financial trends, and bearish technicals creates a challenging setup for investors.
Key Strengths & Risk Factors
KEY STRENGTHS
- Strong Balance Sheet: Net cash position with debt to equity of -0.28 provides financial flexibility and reduces risk
- Market Leadership: Established brand portfolio in Ayurvedic and herbal categories with over 250 products
- Consistent Dividend Payer: High dividend payout ratio of 80.21% with yield of 1.71% rewards shareholders
- Zero Promoter Pledging: Indicates financial stability and confidence of controlling shareholders
- Robust Interest Coverage: EBIT to interest ratio of 26.22x demonstrates strong debt servicing capability
- Efficient Working Capital: Debtors turnover ratio at 18.44 times ensures quick receivables collection
- Positive YoY Growth: Q4 FY26 revenue up 7.35% and net profit up 15.14% year-on-year shows underlying resilience
KEY CONCERNS
- Expensive Valuation: P/E of 44.53x and PEG of 13.38x difficult to justify given growth trajectory
- Margin Compression: Operating margin declined to 15.20% in Q4 FY26 from 20.63% in previous quarter
- Anaemic Growth: Five-year sales growth of 7.39% and EBIT growth of 3.06% significantly below sector standards
- High Non-Operating Income: Other income at 36.95% of PBT raises concerns about core profitability sustainability
- FII Exodus: Foreign institutional holding declined from 12.68% to 9.98% over past year signals waning confidence
- Long-Term Underperformance: Stock declined 10.25% over five years whilst Sensex gained 57.50%
- Deteriorating ROE: Latest ROE of 16.51% down from average of 18.97% indicates declining capital efficiency
Outlook: What to Watch
POSITIVE CATALYSTS
- Margin recovery in Q1-Q2 FY27 as seasonally stronger quarters arrive
- Rural demand revival driving volume growth acceleration
- Successful new product launches in health and wellness categories
- Market share gains in key categories like oral care and hair care
- Stabilisation or reversal of FII selling trend
RED FLAGS TO MONITOR
- Further margin compression in coming quarters below 15% operating margin
- Continued single-digit revenue growth unable to support premium valuation
- Rising interest costs indicating increased leverage or working capital stress
- Further decline in FII or mutual fund holdings signalling institutional exodus
- Inability to reduce dependence on non-operating income for profitability
The Verdict: Quality Franchise, Expensive Entry Point
Score: 35/100
For Fresh Investors: Avoid initiating positions at current levels. The combination of expensive valuation (P/E 44.53x, PEG 13.38x), negative financial trends, and anaemic long-term growth creates an unfavourable risk-reward profile. Wait for a significant correction of 20-25% or clear evidence of operational turnaround before considering entry.
For Existing Holders: Consider reducing exposure or exiting positions, particularly if purchased at higher levels. The stock's five-year decline of 10.25% against Sensex gains of 57.50% demonstrates persistent underperformance. Reallocate capital to better-positioned FMCG names or sectors with superior growth visibility. Hold only if conviction in long-term turnaround remains high and portfolio allocation is modest.
Fair Value Estimate: ₹380-₹400 (20-21% downside from current levels)
Note- ROCE= (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
âš ï¸ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions.
